UB2 QUANTIFYING THE RELATIONSHIP BETWEEN DISEASE SEVERITY, UTILITY AND HEALTH CARE RESOURCE USE IN CROHN'S DISEASE  by Weston, AR et al.
A4 Abstracts
lated for paired observations between IBDQ and EQ-5D (n =
3320) and IBDQ and SF-6D (n = 3230). Least square regression
models were investigated. RESULTS: The decile analysis demon-
strated a consistent positive relationship with both utility scores.
The correlations between the IBDQ and both the EQ-5D and SF-
6D were statistically highly signiﬁcant (p < 0.0001). The corre-
lation coefﬁcients for IBDQ with SF-6D and with EQ-5D were
0.85 and 0.76 respectively. A simple linear least square regres-
sion model of the relationship between EQ-5D and IBDQ
explained 46% of the variance. A visual inspection of the 
residuals plot for the IBDQ/SF-6D model suggested some non-
linearity and an improved non-linear model explained 72% of
the variance. The comparison of the two sets of values demon-
strated the commonly observed ceiling effect for the EQ-5D 
and ﬂoor effect for the SF-6D and provided added face validity
for the transformations. CONCLUSIONS: Given the strength,
consistency, and predictable characteristics of the relationships,
the algorithms appear to provide valuable and valid methods 
to estimate utilities from IBDQ scores in trials of Crohn’s 
disease patients that have collected IBDQ scores but not utilities.
The generalisability of this relationship to other groups of
patients, for which the IBDQ is appropriate, should be 
investigated.
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OBJECTIVES: To assess the relationship between (i) disease
severity and quality of life and (ii) disease severity and health
care resource use, in patients with Crohn’s disease. METHODS:
A prospective, cross sectional, pharmacoeconomics study was
conducted in ﬁve centres in Australia, with patients recruited by
specialist gastroenterologists. Each patient completed question-
naires comprising demographic, disease and health care utilisa-
tion questions, together with the disease-speciﬁc Inﬂammatory
Bowel Disease Questionnaire (IBDQ) and the Assessment of
Quality of Life (AQoL) multi-attribute utility instrument.
Disease severity was assessed by the gastroenterologist, using the
Crohn’s Disease Activity Index (CDAI). RESULTS: Of the 154
patients recruited, 11 were excluded due to incomplete datasets
or signiﬁcant co-morbidity. The 143 patients analysed had a
broad range of disease severity (CDAI 36-446), and included
23% with enterocutaneous ﬁstulae. Stepwise regression analyses
showed a negative relationship between disease severity and
quality of life—irrespective of whether the latter was measured
by the IBDQ (p < 0.0001) or the AQoL utility instrument (p <
0.0001). Age, gender and years since diagnosis did not signiﬁ-
cantly impact upon either of the quality of life outcomes. Health
care resource utilisation increased with increasing CDAI (p <
0.001), with hospital admissions being the largest component
cost. Even when patients with ﬁstulae were excluded, the mean
treatment cost for the most severe group (CDAI >= 220) was
AUD$7852 annually, excluding medications. Finally, despite
their young age (mean = 38yrs), 27% of patients received a Gov-
ernment beneﬁt; with the majority of these stating that this was
primarily due to their Crohn’s disease. CONCLUSIONS: More
severe Crohn’s disease is associated with poor quality of life for
patients and places considerable burden upon health care and
social welfare resources.
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OBJECTIVES: To compare 2 preference-based measures of
health, the EQ-5D and the SF-6D, in patients with pulmonary
arterial hypertension (PAH). METHODS: PAH patients (n =
278) were administered the EQ-5D and SF-36 questionnaires in
a sildenaﬁl clinical study. Comparisons of the utility indices of
the EQ-5D and the SF-36 (the SF-6D) were conducted using the
study baseline data. Comparisons were made using the total
group of patients, and a sub-group analysis by functional class
was also conducted. Functional class was assessed using the
WHO criteria for functional capacity and therapeutic class in
patients with PAH; there are 4 WHO functional classes (FC
I–IV), with higher classes associated with greater limitations in
physical activity. RESULTS: In the total group of patients, the
mean (SD) utility index scores of the EQ-5D and the SF-36 were
similar (0.632 [0.254] vs. 0.627 [0.116]), and the single-measure
intra-class correlation coefﬁcient between them was 0.51. Base-
line FC for treated patients was distributed as follows: FC I,
0.4%; FC II, 38.6%; FC III, 57.6%; FC IV, 3.2%. Given the low
proportions of subjects in FC I and FC IV, analyses were per-
formed on the combined groups of FC I/II and FC III/IV. The
mean (SD) utility index score of the EQ-5D exceeded the SF-6D
score in FC I/II patients (0.720 [0.205] vs. 0.672 [0.122]), but
was lower than the SF-6D score in FC III/IV patients (0.574
[0.266] vs. 0.597 [0.102]). CONCLUSIONS: The EQ-5D and
the SF-36 utility indices provide similar estimates for PAH
patients overall. However, the agreement between the instru-
ments is not consistent over the range of functional classes seen
in PAH patients.
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OBJECTIVES: Currently, there is only limited research into the
main determinants of QoL in patients with psoriatic arthritis
(PsA). With a number of novel treatments for PsA emerging, we
examined the associations between clinical outcomes and health
utilities for the purposes of economic evaluation. METHODS:
Patient-level data from a pivotal, Phase III, randomized con-
trolled trial of the fully human, anti-tumor necrosis factor mon-
oclonal antibody, adalimumab, vs. placebo in the treatment 
of PsA were analyzed. All potentially relevant outcomes were
included: patient-reported functional loss measured by the
Health Assessment Questionnaire Disability Index (HAQ-DI),
physician’s assessment of psoriasis severity from the Psoriasis
Area Severity Index (PASI), tender and swollen joint counts (TJC,
SJC), age, sex, and disease duration. All measurements were col-
lected for patients at baseline and Weeks 12 and 24. The health
utility measurement, the SF-6D was derived from responses to
the Short Form-36, a generic QoL questionnaire. Multiple linear
regressions using generalized estimating equations were
employed to identify signiﬁcant predictors of the SF-6D.
RESULTS: Mean baseline characteristics for 313 patients
